NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 122 filers reported holding NURIX THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,469,007 | +16.5% | 568,576 | +48.1% | 0.00% | 0.0% |
| Q2 2023 | $3,835,750 | +12.2% | 383,959 | -0.2% | 0.00% | 0.0% |
| Q1 2023 | $3,417,379 | -18.7% | 384,840 | +0.5% | 0.00% | 0.0% |
| Q4 2022 | $4,204,407 | -13.9% | 382,915 | +2.2% | 0.00% | -50.0% |
| Q3 2022 | $4,881,000 | +32.6% | 374,573 | +29.0% | 0.00% | +100.0% |
| Q2 2022 | $3,681,000 | -2.7% | 290,459 | +7.6% | 0.00% | 0.0% |
| Q1 2022 | $3,784,000 | -50.4% | 270,055 | +2.4% | 0.00% | -50.0% |
| Q4 2021 | $7,633,000 | -1.9% | 263,640 | +1.5% | 0.00% | -33.3% |
| Q3 2021 | $7,783,000 | +125.9% | 259,760 | +100.0% | 0.00% | +200.0% |
| Q2 2021 | $3,446,000 | -1.9% | 129,888 | +15.0% | 0.00% | 0.0% |
| Q1 2021 | $3,512,000 | +38.9% | 112,935 | +46.9% | 0.00% | 0.0% |
| Q4 2020 | $2,528,000 | +0.3% | 76,871 | +6.5% | 0.00% | 0.0% |
| Q3 2020 | $2,521,000 | – | 72,209 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |